Application for Quotation of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Reinstatement to Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Proposed issue of securities - 2 March 2023
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Half Yearly Accounts 31 December 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Investor Presentation Half Year Results 31 Dec 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Nova Eye Completes $8m Placement
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Suspension from Official Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
28 Feb, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
27 Feb, 2023
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack
31 Jan, 2023
Additional Clinical Role for 2RT
ASX Announcement AlphaRET
25 Jan, 2023
Status of Market Clearance for iTrack Advance in the USA
ASX Announcement General iTrack Molteno3 AlphaRET
12 Dec, 2022
AGM Presentation 2022
ASX Announcement General iTrack Molteno3 AlphaRET
17 Nov, 2022
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack Molteno3 AlphaRET
16 Nov, 2022
AlphaRET Completes Initial Recruitment of Investigator Sites for 2RT® Confirmatory Pivotal Study
ASX Announcement General iTrack AlphaRET
24 Oct, 2022
Notice of Annual General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
14 Oct, 2022
2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022
ASX Announcement General AlphaRET
15 Sept, 2022
AGM Date and Directors Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
14 Sept, 2022
EYE 2RT Webinar Prof Guymer
ASX Announcement General iTrack Molteno3 AlphaRET
9 Sept, 2022
EYE FY22 Appendix 4G & Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Appendix 4E & Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
Sales Performance Glaucoma Surgical Devices Segment
ASX Announcement General iTrack Molteno3
8 July, 2022
Nova Eye Medical Launches iTrack Advance
ASX Announcement General iTrack Molteno3 AlphaRET
8 June, 2022
2RT Pivotal Study and Regulatory Pathway Presentation
ASX Announcement General AlphaRET
3 May, 2022
Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA
ASX Announcement General AlphaRET
3 May, 2022
EYE Appointment to AGS Board
ASX Announcement iTrack
31 Mar, 2022
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More